Skip to main content
BioInvent International logo

BioInvent International — Investor Relations & Filings

Ticker · BINV ISIN · SE0015244520 LEI · 549300E7QRHEF2IJUY10 ST Manufacturing
Open in API
Filings indexed 679 across all filing types
Latest filing 2021-12-17 Regulatory Filings
Country SE Sweden
Listing ST BINV

About BioInvent International

https://www.bioinvent.com/en

BioInvent International is a clinical-stage company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates for its clinical pipeline. BioInvent's operations include an in-house manufacturing facility to produce antibodies for its preclinical studies and clinical trials, with the goal of developing treatments that can transform the lives of cancer patients.

Recent filings

Filing Released Lang Actions
BioInvent announces positive early data from ongoing solid cancer trial of BI-1206 in combination with pembrolizumab
Regulatory Filings Classification · 98% confidence The document is a press release dated December 17, 2021, announcing positive early clinical trial data for a drug candidate (BI-1206). It contains key highlights, quotes from the CEO, and information about an upcoming Key Opinion Leader (KOL) Webinar to discuss the data. Crucially, the final section states: "This information is information that BioInvent International is obliged to make public pursuant to the EU Market Abuse Regulation." This strongly suggests a mandatory regulatory disclosure. Since it is an announcement of clinical results/updates rather than a comprehensive periodic report (like 10-K or IR), and it is a general regulatory announcement mandated by market rules, the most appropriate classification is Regulatory Filings (RNS), which serves as the general regulatory announcement fallback category for non-standard reports. It is not an Earnings Release (ER) as it focuses on clinical trial data, not period-end financial performance highlights.
2021-12-17 English
BioInvent presenterar positiva tidiga data från den pågående studien av BI-1206 i kombination med pembrolizumab för behandling av solida tumörer
Regulatory Filings Classification · 95% confidence The document is a press release dated December 17, 2021, announcing positive early data from a clinical study (BI-1206 in combination with pembrolizumab). It details clinical responses, quotes the CEO, and includes standard company boilerplate information. Crucially, the end of the document explicitly states: "Denna information är sådan information som BioInvent International är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning." (This information is information that BioInvent International is obliged to disclose pursuant to the EU's Market Abuse Regulation.) Furthermore, it lists an attached file (a PDF link) which is likely the full report or presentation. Since this document is an announcement *about* data/results and references an attached file, and it is a general regulatory disclosure under MAR, it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were quarterly results, but since it's specific clinical trial data announcement, RNS is the most appropriate general regulatory category, as it is not a full financial report (10-K/IR) or a dedicated management discussion (MDA). Given the context of clinical trial updates being mandatory disclosures, RNS is the best fit among the options provided for a general regulatory announcement not covered by other specific codes like ER or AR.
2021-12-17 Swedish
BioInvents senaste BI-1206 NHL-data som presenteras på ASH visar på ökat och varaktigt svar hos återfallspatienter
Earnings Release Classification · 99% confidence The document is a press release dated December 11, 2021, announcing updated interim data for the drug candidate BI-1206, which was presented at the American Society of Hematology (ASH) Annual Meeting. It details clinical trial results (ORR, DCR) and includes quotes from the CEO, information about an upcoming KOL webinar, and standard corporate boilerplate. This type of announcement, focusing on clinical trial data presentation at a major conference, is typically classified as an Earnings Release (ER) if it were quarterly results, or more generally as a Regulatory Filing (RNS) if it's a specific, non-standard announcement. However, given the context of presenting clinical data updates, it functions as an immediate release of material information to the market, often preceding a formal quarterly report or being a standalone material event disclosure. Since it is not a full financial report (10-K or IR), nor a proxy statement (DEF 14A), nor a management discussion (MDA), and it is a direct announcement of results, the most fitting category among the options for a material, non-standard disclosure is the general Regulatory Filings (RNS), as it is a broad category for regulatory announcements that don't fit elsewhere, or potentially an Earnings Release (ER) if the company treats clinical updates as periodic results announcements. Given the focus is purely on clinical data presentation and not comprehensive financial performance for a period, RNS is the safest general classification for a material, non-standard disclosure. However, if the company regularly issues these clinical updates as their primary form of periodic disclosure, ER might be considered. Since it explicitly mentions the data is being presented at a conference and is a press release, RNS (Regulatory Filings) is the most appropriate fallback for a material, non-standard announcement. FY 2021
2021-12-11 Swedish
BioInvent’s latest NHL data at ASH show increased and sustained responses to BI-1206 in relapsed patients
Legal Proceedings Report Classification · 99% confidence The document is a press release dated December 11, 2021, announcing updated interim top-line data from a clinical trial (BI-1206) presented at the American Society of Hematology Annual Meeting (ASH 2021). It details clinical results (ORR, DCR) and includes management commentary and plans for a forthcoming KOL webinar. This structure—announcing key results from a recent event or period without being the full, comprehensive financial report (like a 10-K or IR)—is characteristic of an Earnings Release (ER) or a general announcement of scientific/operational progress. Since it focuses on clinical trial results and not quarterly financial performance highlights, it is best classified as an announcement of scientific/operational progress. However, among the provided codes, 'ER' (Earnings Release) is often used broadly for initial results announcements, but 'RNS' (Regulatory Filings/General Announcement) is a strong candidate for press releases detailing clinical data updates that aren't standard financial reports. Given the content is a press release announcing scientific data and upcoming investor events, and it is not a formal financial report (10-K, IR, MRQ), it fits best as a general regulatory/company announcement, which aligns with RNS, or potentially ER if the company treats clinical updates as 'earnings' equivalents. Since it is a press release announcing data, and the document length is substantial (7402 chars), it is more than just a brief notification (RPA). I will classify it as an Earnings Release (ER) as it announces key performance indicators (clinical response rates) for a drug candidate, which drives investor interest, or RNS as a general announcement. Given the focus on clinical data updates, RNS is the most appropriate fallback for non-financial, non-statutory announcements. However, in many contexts, press releases announcing key operational milestones like clinical data are often categorized under ER if they drive market perception similarly to financial results. I will lean towards RNS as the most neutral fit for a clinical data press release that isn't explicitly a financial earnings report.
2021-12-11 English
BioInvent presenterar ytterligare positiva kliniska data för BI-1206 på ASH-konferensen i december 2021
Earnings Release Classification · 99% confidence The document is a press release dated November 4, 2021, announcing positive interim clinical data for a drug candidate (BI-1206) that will be presented at the American Society of Hematology (ASH) Annual Meeting in December 2021. It details clinical results (ORR, DCR), provides management commentary, and mentions future events (KOL-event). Crucially, the document ends with a section titled "Bifogade filer" (Attached files) which links to a PDF of the announcement itself. Since this is an announcement about data presentation and the release itself is short and points to an attached document (or the content of the announcement), it fits the criteria for a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given that it is a specific announcement about the publication/presentation of clinical data, RPA is a strong candidate, but since it is a general press release format announcing results and future presentations, RNS (Regulatory Filings - general regulatory announcements/press releases) is often the appropriate catch-all for non-standard financial reports, especially when the content is primarily clinical/research updates rather than mandatory financial statements (like 10-K or IR). However, since the content is an announcement of data being presented at a conference, and it is not a formal financial report, RNS is the most suitable general regulatory category for this type of corporate news release that doesn't fit ER, CT, or LTR. FY 2021
2021-11-04 Swedish
BioInvent to show further positive BI-1206 clinical data in December at ASH 2021
Regulatory Filings Classification · 95% confidence The document is a press release dated November 4, 2021, announcing that BioInvent will present updated clinical data for its drug candidate BI-1206 at the ASH 2021 conference in December. It details interim results (ORR, DCR) and mentions that the abstract is available online and that a KOL event will follow. Crucially, the document ends with a section titled 'Attachments' which links to a PDF of the announcement itself, and the final paragraph states: 'This information is information that BioInvent International is obliged to make public pursuant to the EU Market Abuse Regulation.' This structure—a brief announcement about forthcoming data presentation and the publication of an abstract, often accompanied by a link to the full release—is characteristic of a general regulatory disclosure or press release that doesn't fit a specific financial report category (like 10-K, IR, or ER). Since it is a general regulatory announcement mandated by market rules (EU Market Abuse Regulation) and doesn't fit ER, CT, IP, or MDA, the most appropriate fallback category is Regulatory Filings (RNS). It is not an Earnings Release (ER) as it focuses on clinical trial data, not period financial results.
2021-11-04 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.